Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Acquisitions & Divestments (2018 - 2025)

Historic Change in Acquisitions & Divestments for Zevra Therapeutics (ZVRA) over the last 6 years, with Q3 2025 value amounting to $60.5 million.

  • Zevra Therapeutics' Change in Acquisitions & Divestments rose 50469.77% to $60.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.2 million, marking a year-over-year increase of 12561.91%. This contributed to the annual value of $25.0 million for FY2024, which is 5771.38% down from last year.
  • Zevra Therapeutics' Change in Acquisitions & Divestments amounted to $60.5 million in Q3 2025, which was up 50469.77% from $12.5 million recorded in Q2 2025.
  • Zevra Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $60.5 million during Q3 2025, with a 5-year trough of $202000.0 in Q4 2024.
  • Its 4-year average for Change in Acquisitions & Divestments is $15.7 million, with a median of $12.5 million in 2025.
  • Per our database at Business Quant, Zevra Therapeutics' Change in Acquisitions & Divestments surged by 306533.33% in 2023 and then plummeted by 9870.72% in 2024.
  • Quarter analysis of 4 years shows Zevra Therapeutics' Change in Acquisitions & Divestments stood at $300000.0 in 2022, then soared by 5108.33% to $15.6 million in 2023, then crashed by 98.71% to $202000.0 in 2024, then soared by 29850.5% to $60.5 million in 2025.
  • Its Change in Acquisitions & Divestments was $60.5 million in Q3 2025, compared to $12.5 million in Q2 2025 and $18.0 million in Q1 2025.